The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
Adlai Nortye Ltd.
ANL · Nasdaq · USD · Market cap $914M · 109 employees
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price10.61 USD at the 13 Nov 2026 close
- Fair valueUnder review: our model's value is 2.17x the price, above our 2.00x limit.
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-13).
- Trend Distribution
- Insiders insiders sold, $83,150, latest filing 2026-09-22
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Adlai Nortye Ltd. holds its Distribution at $10.61. The statistical read favours the sellers, held for 24 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 24 days |
| Price at the screen | $10.61 |
| Valuation | N/A trailing · -30.83 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.11 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 76.60% | Below 33% | Interest-bearing debt is 76.6% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 27.43% | Below 49% | Money owed to the company is 27.4% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Adlai Nortye's business is in a permissible area, but its interest-bearing debt is about 77% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ANL's ethical verdict changes
Today ANL does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.17x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 5 covering, consensus Strong Buy. The average target sits +117% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -30.8x |
| EPS, trailing | -1.11 |
| EPS, forward | -0.37 |
| Revenue growth | +178.1%growing very fast |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -414.0%not currently earning a positive return on equity |
| FCF yield | -5.08% |
| Current ratio | 0.65below 1: short-term bills exceed liquid assets |
| Beta | 1.11moves a little more than the market |
| Short interest, float | 0.06% |
| 52-week range | 0.88 - 17.25 |
| Market cap | $914M |
| Employees | 109 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeANL trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 22.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 29% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 35.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29. Insiders have been net sellers over the past quarter.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 11.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 109% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 574%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (5 analysts) rates it strong buy, with a mean price target of $29.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-22 | Ji Ping | Dir | S - Sale | 5,000 | $83,150 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-10-13 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-07 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-10-02 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-10 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-09-10 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $12.96 | -18.3% | · | $817 | -18.3% |
| 2 months | $11.16 | -5.2% | · | $949 | -5.2% |
| 3 months | $8.36 | +26.6% | · | $1,266 | +26.6% |
| 6 months | $1.28 | +727.0% | · | $8,270 | +727.0% |
| 1 year | $1.57 | +574.2% | · | $6,742 | +574.2% |
| 2 years | $3.81 | +177.8% | · | $2,778 | +177.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ANL does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.